Scholar Rock, a Cambridge, MA-based developer of niche modulators that selectively target protein growth factors in the disease microenvironment, raised $20m in Series A funding.
The round was led by ARCH Venture Partners, with participation from founding investors Polaris Partners and Timothy Springer and new investors EcoR1 Capital and The Kraft Group.
The company intends to use the funds to advance proprietary niche modulators from preclinical research toward clinical drug development.
Founded by Professors Timothy Springer, PhD, and Leonard Zon, MD, both of Boston Children’s Hospital and Harvard Medical School, and led by Nagesh Mahanthappa, PhD, Chief Executive Officer and President, Scholar Rock focuses on discovering and developing niche modulators, a novel class of biologic therapies that selectively modulate the activation of growth factors in the disease microenvironment. The company’s initial proprietary and partnered drug discovery programs target specific growth factors, including members of the TGF-beta superfamily, which are present in the microenvironments of diseases such as fibrosis, diseases of the musculoskeletal systems and autoimmune diseases.